Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 30-Jun 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5048580016 | Bismuth biskalcitrate 140 mg and metronidazole 125 mg and tetracycline hydrochloride 125 mg oral capsule | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5048581017 | Product containing precisely bismuth biskalcitrate 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | en | Fully specified name | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5456436018 | Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5456437010 | Bismuth subcitrate potassium 140 mg and metronidazole 125 mg and tetracycline hydrochloride 125 mg oral capsule | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Is a | Product containing only bismuth subcitrate potassium and metronidazole and tetracycline in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has manufactured dose form | Oral capsule | true | Inferred relationship | Some | ||
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has unit of presentation | Capsule (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Plays role | Antibacterial therapeutic role (role) | false | Inferred relationship | Some | ||
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Tetracycline hydrochloride | true | Inferred relationship | Some | 1 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Tetracycline hydrochloride | true | Inferred relationship | Some | 1 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Metronidazole (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Metronidazole (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Bismuth biskalcitrate | false | Inferred relationship | Some | 3 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Bismuth biskalcitrate | false | Inferred relationship | Some | 3 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 3 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 3 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has precise active ingredient | Bismuth subcitrate potassium (substance) | true | Inferred relationship | Some | 3 | |
| Product containing precisely bismuth subcitrate potassium 140 milligram and metronidazole 125 milligram and tetracycline hydrochloride 125 milligram/1 each conventional release oral capsule (clinical drug) | Has basis of strength substance (attribute) | Bismuth subcitrate potassium (substance) | true | Inferred relationship | Some | 3 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets